Fadi

There is no image.

Mitiglinide

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fadi

What is Fadi? (Mitiglinide)

Property	Description
Active ingredient	Mitiglinide
Form	Oral Tablet
Pharmacological class	Meglitinide (Glinide) Class
Common use	Managing Type 2 Diabetes Mellitus
Origin	Synthetic Compound (Succinic acid derivative)

Fadi (Mitiglinide): Identity and Active Composition

Fadi is a pharmaceutical preparation delivered as an oral tablet for the management of blood glucose levels in adults with Type 2 Diabetes Mellitus. The active therapeutic component is Mitiglinide, provided as Mitiglinide Calcium Hydrate, which is a synthetic compound derived from succinic acid. This medication is typically a prescription-only drug in several global regions. As a single-ingredient product, Fadi relies exclusively on the pharmacological actions of Mitiglinide, distinguishing it from combination treatments.

Classification and Pharmacological Type (Meglitinide Class)

Fadi is formally categorized as an Oral Hypoglycemic Agent and belongs to the Glinide class, also known as the Meglitinide class of antidiabetic agents. The mechanism is clinically recognized as that of an insulin secretagogue, a substance that stimulates the body's pancreatic beta-cells to release stored insulin. Pharmacological studies confirm that Mitiglinide's activity features a notably rapid onset and short duration of action, properties integral to its classification within the meglitinides.

General Purpose: Addressing Postprandial Blood Sugar

The primary general benefit of Fadi is assisting in the targeted control of postprandial hyperglycemia, which refers to the sharp elevation in blood glucose occurring after a meal. The short-acting nature of the compound is specifically advantageous for mitigating this glucose spike, supporting the maintenance of overall stable blood sugar levels. The drug is utilized for managing post-meal glucose increases, which is a key therapeutic goal in diabetes management.

Regulatory References

Mitiglinide Classification (DrugBank)

What side effects are possible with Fadi?

Possible Side Effects and Safety Information

The safety profile of Fadi (Mitiglinide) is based on the documented adverse reactions and official regulatory constraints for this meglitinide-class agent.

Adverse Reaction Classifications

The most significant and frequently reported adverse reaction is Hypoglycemia (low blood sugar), which is also classified as a potential serious adverse reaction by regulatory authorities. Other adverse effects are officially grouped by the system-organ class involved:

Common Adverse Reactions: The regulatory documentation commonly lists effects such as Headache and Upper Respiratory Tract Infection. Gastrointestinal disturbances are also commonly reported, including Constipation and Abdominal Distension.
Rare Adverse Reactions: Less frequently reported effects include certain Hematological Disorders (e.g., anemia, leukopenia), Hypersensitivity Reactions, and signs of Liver Dysfunction (such as general malaise or jaundice).

Serious Safety Constraints

Severe adverse reactions documented in regulatory sources include profound Severe Hypoglycemia that may lead to unconsciousness. Additionally, caution is noted regarding severe Liver Dysfunction and, in patients with pre-existing conditions, a potential association with Myocardial Infarction.

Population-Specific Limitations

The label defines specific populations where use is restricted or requires particular caution:

Contraindications: Use is strictly prohibited in patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis. It is also restricted during periods of acute metabolic stress, such as severe infection or major trauma.
Caution Required: Due to altered drug clearance, caution is required for individuals with Renal Dysfunction or Hepatic Dysfunction, as this may increase the risk of hypoglycemia. Use is not recommended during pregnancy or breastfeeding.

This structure reflects how government regulatory documents formally organize and communicate the spectrum of recognized risks and limitations.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

The primary, officially documented clinical manifestation of Fadi (Mitiglinide) overdose is severe hypoglycemia, resulting from excessive stimulation of insulin release. This imbalance in blood glucose may manifest with symptoms such as dizziness, sweating, confusion, shakiness, and intense hunger. The physiological systems affected include the metabolic system and, secondarily, the central nervous system, which may lead to critical, life-threatening outcomes.

Overdose Classifications

Overdose leading to uncorrected, severe hypoglycemia is classified in regulatory documents as a potentially life-threatening scenario. Management procedures are defined by official regulatory documents, which explicitly state that there is no specific antidote for Mitiglinide overdose.

Resulting Overdose Structure

Official overdose statements require specific actions in the event of accidental consumption of more than the prescribed amount.

Immediate medical attention or consultation with a doctor is required if an overdose is suspected.
Immediate hospitalization is mandated for overdose resulting in severe neurological effects, such as seizures or loss of consciousness.
Treatment is strictly symptomatic and supportive, typically involving the administration of glucose or sugar for mild symptoms, and intravenous glucose infusion for severe cases.
Prolonged hospital monitoring, including repeated blood glucose measurements for up to 24 hours, is necessary to prevent the recurrence of hypoglycemia.

Connection to the overall overdose profile: Regulatory documents define this overdose profile by the singular risk of severe hypoglycemia and its complications, which determines all required emergency actions. This dictates that intervention must focus on prompt glucose correction and intensive observation due to the absence of a pharmacological antidote.

Therapeutic Uses of Fadi

Fadi (Mitiglinide) is a therapeutic option for adults with Type 2 Diabetes Mellitus, relevant when blood sugar levels remain difficult to manage despite initial lifestyle support and for the general management of blood glucose levels.

It is primarily used to address the rapid, episodic increase in blood glucose that occurs following food consumption (postprandial hyperglycemia), and, in the clinical scenario of inadequate existing management, it is considered relevant in clinical settings that involve combining therapeutic agents. The medication may assist with maintaining functional stability when symptoms create noticeable physiological strain.

By helping to manage the severity of these mealtime glucose spikes, the medication supports the patient in working toward the therapeutic goal of long-term glycemic management. This action contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress.

Quick Fact: Support for Acute Glucose Spikes
Therapeutic Target: Postprandial Hyperglycemia
Usage Context: Inadequate Glycemic Control
Patient Benefit: Supports the process of managing long-term blood sugar levels

Eligibility and Restrictions for Use

Official Eligibility Rules for Fadi (Mitiglinide)

The population eligibility for Fadi is strictly defined by government regulatory agencies, establishing clear criteria for appropriate use. The medication is intended only for adults with Type 2 Diabetes Mellitus.

Contraindications

Fadi is contraindicated in specific patient populations, meaning its use is absolutely prohibited. This includes individuals with Type 1 Diabetes Mellitus, as well as patients presenting with Diabetic Ketoacidosis (including diabetic coma or precoma). Use is also prohibited in patients with a known hypersensitivity to Mitiglinide or any of the inactive ingredients.

Restricted and Non-Eligible Groups

Population Group	Regulatory Status
Pediatric Patients (Under 18)	Safety and effectiveness not established; use is not recommended.
Pregnancy and Lactation	Generally not recommended.
Severe Hepatic Impairment	Use is restricted or requires special caution.
Severe Renal Impairment	Use is restricted or requires special caution.

These official rules serve to define the population that can safely and effectively use the medicine based on authorized regulatory data.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The formal interaction profile for Fadi (Mitiglinide) addresses agents that either enhance or reduce its blood glucose-lowering effect, and includes specific restrictions on co-administration with other diabetes treatments.

Regulatory Restrictions and Contraindicated Combinations

Classification	Interacting Agents	Official Constraint Description
Do Not Combine	Sulfonylurea-type agents	Not recommended due to unconfirmed additive clinical effects and safety.
Safety Unconfirmed	Biguanides, Pioglitazone	Efficacy and safety of concomitant use are not confirmed in official documents.

Pharmacodynamic and Efficacy Interactions

Interaction statements describe two types of pharmacodynamic effects:

Enhanced Glucose-Lowering Effect: Co-administration with agents such as insulin preparations, sulfanilamide, and certain beta-blockers may enhance Fadi's effect. This requires careful examination with blood glucose monitoring.
Reduced Glucose-Lowering Effect: Substances including adrenocortical hormones and thiazide or loop diuretics are documented as potentially reducing Fadi's therapeutic effect, which may lead to an increase in blood glucose levels.

Metabolic and Substance Interactions

Mitiglinide is mainly cleared from the body through glucuronidation mediated by the metabolic enzymes UGT1A9 and UGT1A3. Altered function in these pathways or through substance use can modify drug exposure.

Alcohol: Excessive ingestion of alcohol is officially documented as a substance interaction that may cause hypoglycemia.

Population-Specific Interaction Notes

Constraints are noted for specific populations due to the drug's clearance: Hepatic dysfunction and renal dysfunction may prolong the drug's elimination and increase the risk of hypoglycemia. Caution is also noted for elderly individuals due to general degeneration of physiological functions that may increase hypoglycemia risk.

Connection to the overall interaction profile (4 sentences):

Regulatory documents define Fadi's interaction structure primarily by establishing formal constraints on combining it with other antidiabetic agents due to unconfirmed safety. The profile clearly documents agents that either enhance or reduce the blood glucose-lowering outcome through pharmacodynamic and efficacy-reducing mechanisms. Official statements also specify the primary metabolic clearance pathway via UGT enzymes, which establishes a foundation for potential pharmacokinetic interactions. This framework establishes the necessary constraints and conditions for co-administration as defined by official regulatory bodies.

Mechanism of Action

The mechanism of action for Fadi involves a dual-domain approach that modulates central nervous system (CNS) activity by influencing both excitatory and inhibitory signaling pathways. This targeted modulation affects the dynamics within hyperexcitable neural networks.

Modulating the GABAergic Inhibitory System

Fadi acts as a Positive Allosteric Modulator (PAM) on GABA-A receptors. By enhancing the effect of the inhibitory neurotransmitter GABA, Fadi increases chloride ion ( Cl^-) flow into the neuron. This molecular event leads to cellular hyperpolarization, which elevates the threshold required for action potential generation. This results in a fundamental reduction in general neuronal excitability, which is a key physiological consequence of the mechanism.

Stabilizing Voltage-Gated Sodium Channels

Fadi also functions as a non-competitive inhibitor of Voltage-Gated Sodium Channels (VGSCs). By blocking Na^+ ion influx, Fadi primarily limits the speed and frequency of action potential propagation, especially in rapidly firing neurons. This action places a ceiling on high-frequency signal discharge, which contributes to the drug's effect on signaling patterns characteristic of motor pathways and hyperexcitable neural activity.

Dosage and Administration Information

Fadi is administered via the oral route as a tablet formulation, including specific Orally Disintegrating (OD) tablet forms. Its usage protocol is strictly defined to ensure proper temporal alignment with food consumption. The standard adult dose is typically 10 mg taken before each major meal. This dosage is not fixed, as clinical guidelines permit the dose to be adjusted, increased, or decreased based on the patient's individual symptoms and current level of blood glucose control.

Administration Scope

Instruction Entity	Detail (Strictly Label-Based)
Route of administration	Oral (by mouth)
Dosing schedule	Standard adult dose is 10 mg three times daily; dosage is adjusted according to glucose control.
Timing in relation to meals	Must be administered just before the meals, specifically within 5 minutes of starting food consumption.
Missed-dose rules	If a meal is skipped, the corresponding dose must also be skipped. Taking two doses at once is prohibited.
Special procedural conditions	Requires careful administration in patients with hepatic impairment or renal impairment

Procedural Structure

The standard use sequence mandates taking the prescribed dose orally three times daily, with each dose tied to a major meal. The primary administration constraint is the strict requirement to take the tablet immediately before eating. This protocol establishes that if a patient skips a meal, the dose associated with that meal must also be omitted. The necessity of treatment, drug selection, and dosage adjustments are continually determined by reviewing the patient's diet and blood glucose status.

Recent Clinical Evidence

Research Evidence Overview for Fadi (Mitiglinide)

This section will provide a high-level, non-advisory summary of the clinical research conducted on Fadi, focusing only on the types of studies, the populations examined, and the primary outcomes evaluated, as reported by regulatory and peer-reviewed sources.

Evidence for Use in Managing Type 2 Diabetes Mellitus

Research explored Fadi in studies examining changes in long-term blood sugar markers. This evidence was primarily conducted through Randomized Controlled Trials (RCTs) of short- to intermediate-term duration (lasting from a few months up to one year), as well as Systematic Reviews. These studies monitored adults with Type 2 Diabetes Mellitus, particularly when blood sugar was not adequately controlled by prior management.

Research examined how Fadi, when studied alone or in addition to other medications like metformin, was evaluated in studies monitoring changes in major blood sugar markers. These studies monitored outcomes related to systemic or functional imbalance, such as average long-term blood sugar, measured by Glycated Hemoglobin (HbA1c), and blood sugar levels taken after a period of fasting (Fasting Plasma Glucose, FPG). Research highlights changes measured during the study period.

However, research highlights that results apply only to the populations studied. Follow-up durations were limited in many comparative trials, and there is limited information for long-term outcomes, particularly regarding long-term health outcomes.

Targeted Research on Postprandial Glucose Control

Targeted research explored Fadi in studies examining outcomes related to the rapid, episodic increase in blood glucose occurring after a meal (known as postprandial hyperglycemia). Studies conducted during periods of increased symptom activity, like immediately after eating, were essential for this evaluation.

In these research scenarios, the primary outcomes monitored were outcomes monitoring physiological strain, specifically acute changes in blood sugar measured 30 minutes to two hours after a meal (Postprandial Plasma Glucose, PPG). Research provides insight into short-term changes in these post-meal glucose spikes, and these findings contribute to the broader evidence landscape.

Evidence is limited regarding the long-term implications of this specific finding. While studies monitored acute changes effectively, evidence is limited and research is ongoing regarding whether research exploring short-term symptom changes translates into a demonstrably lower risk of serious, long-term health issues like cardiovascular disease or mortality.

Key Research Gaps and Areas of Uncertainty

Research contributes to the broader evidence landscape, but evidence highlights what is known — and what is still uncertain. The primary research limitations noted in scientific reviews include the modest sample sizes of many key comparative trials, meaning findings describe group patterns, not personal outcomes.

A major area of uncertainty is the lack of prospective data establishing the long-term link between Fadi and outcomes related to preventing macrovascular complications. While short-term outcomes are monitored, the long-term effects are not fully established. Comparative evidence is lacking for certain head-to-head comparisons with newer antidiabetic agents, and data for certain high-risk groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Fadi (FAQ)

Q: Is Fadi considered a long-term or short-term treatment?

A: Official regulatory research available for Fadi has focused on studies with short- to intermediate-term durations, which typically last up to one year. Official documents indicate there is limited information regarding long-term health outcomes associated with use.

Q: How long does it usually take for Fadi to start working?

A: Fadi is classified as a Glinide-class medication, which is pharmacologically confirmed to feature a rapid onset of action after it is administered. This rapid action is what allows the medication to help manage the immediate rise in blood sugar that occurs after a meal.

Q: Does Fadi cause weight gain or loss?

A: Official patient information documents state that weight gain is listed among the possible adverse reactions reported in clinical data. This type of information comes from the data collected during clinical use.

Q: Can Fadi be taken by older adults?

A: The medication is described as intended for adults with Type 2 Diabetes Mellitus. However, official regulatory documents note that caution is required for elderly individuals because general age-related changes may increase the potential risk of developing low blood sugar (hypoglycemia).

Q: What is the difference between Fadi and similar medicines that treat the same thing?

A: Fadi belongs to the Glinide (Meglitinide) class of oral hypoglycemic agents. This classification is based on its pharmacological profile, which includes a rapid onset and short duration of action, helping to differentiate it from other types of oral medications used to lower blood glucose.

Q: What does the research say about the long-term use of Fadi?

A: Regulatory reviews state that while short-term outcomes have been monitored, the evidence has limitations. Specifically, there is a lack of prospective data that establishes a clear long-term link between the medication and preventing serious events, such as cardiovascular issues (macrovascular complications).

Q: Why do some people feel Fadi is not effective for them?

A: Research notes a limitation regarding the modest sample sizes of many key comparative trials, which means findings describe group patterns rather than personal outcomes. This highlights the varied nature of individual responses to medication.

Q: What is the risk of serious side effects with Fadi?

A: The official safety profile documents several severe adverse reactions. These include profound Severe Hypoglycemia (very low blood sugar), severe Liver Dysfunction, and a potential association with Myocardial Infarction (heart attack) in patients with pre-existing conditions.

Q: Can I drive or operate machinery after taking Fadi?

A: The official label notes that this medicine may cause dizziness and light-headedness, especially due to the risk of hypoglycemia (low blood sugar). Official patient information describes that close attention is advised when engaging in dangerous activities, such as driving a car or operating machinery.

Q: Is Fadi safe to use for teenagers?

A: Safety and effectiveness for Pediatric Patients (Under 18) have not been established in official regulatory documents. Because of this lack of data, use is not recommended in this group.

Q: What is the scientific name of the active ingredient in Fadi?

A: The active ingredient in Fadi is Mitiglinide. This is provided in the formulation as Mitiglinide Calcium Hydrate. It is categorized as a synthetic compound.

Q: Why is Fadi only available by prescription?

A: The medication is formally classified as an Oral Hypoglycemic Agent. Due to its pharmacological actions and its use for managing a chronic condition like Type 2 Diabetes Mellitus, it is legally designated as a prescription-only drug in many global regions.

Q: What kind of studies were done to get Fadi approved?

A: Regulatory approval was based on studies including Randomized Controlled Trials (RCTs) of short- to intermediate-term duration, along with Systematic Reviews. These studies monitored outcomes related to blood sugar markers.

Q: Does Fadi have a different formulation or strength?

A: The drug is available as an oral tablet formulation and also in specific Orally Disintegrating (OD) tablet forms.

How should Fadi be stored and disposed of?

How to Store and Dispose of Fadi (Mitiglinide)

Storage and disposal instructions for Fadi are strictly defined by regulatory labeling to maintain product stability and safety. The tablets must be stored at a temperature below 30°C (86°F) and must not be refrigerated or frozen.

Official Requirements

Condition	Regulatory Mandate
Container Protection	Keep the tablets in the original package and the outer carton to protect the contents from light and moisture.
Child Safety	Store the medicine out of the sight and reach of children.
Disposal	Dispose of unused or expired Fadi via an authorized drug take-back program or according to local pharmaceutical waste regulations. Do not dispose of the tablets via wastewater or household trash.